Filing Details
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) filed a Form 8-K with the Securities and Exchange Commission on July 28, 2026, disclosing a material event.
8k filedNASDAQ:KNSA
Kiniksa Pharmaceuticals International, plc (KNSA) Reports Material Event to SEC
Filing Details Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) filed a Form 8-K with the Securities and Exchange Commission on July 28, 2026, disclosing a material event.…
Market Context
Kiniksa Pharmaceuticals International, plc's stock currently trades at $79.44 with a market capitalization of $3.0B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Kiniksa Pharmaceuticals International, plc's stock.
All SEC filings for Kiniksa Pharmaceuticals International, plc are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View KNSA Stock Page
Frequently Asked Questions
Where can I read KNSA's SEC filings?
Browse all filings on our KNSA SEC filings page.
What types of SEC filings does Kiniksa Pharmaceuticals International, plc file?
Public companies like Kiniksa Pharmaceuticals International, plc file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.